menu
    • menu
    [{"orgOrder":0,"company":"Exela Pharma Sciences, LLC.","sponsor":"Avadel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Neostigmine Methylsulfate","moa":"Acetylcholinesterase","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Exela Pharma Sciences, LLC.","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Exela Pharma Sciences, LLC. \/ Exela Pharma Sciences, LLC.","highestDevelopmentStatusID":"15","companyTruncated":"Exela Pharma Sciences, LLC. \/ Exela Pharma Sciences, LLC."}]

    Find Clinical Drug Pipeline Developments & Deals by Exela Pharma Sciences, LLC.

    Menu

    Exela Pharma Sciences, LLC.

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Exela Pharma Sciences, LLC.

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Exela Pharma Sciences, LLC.

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neostigmine Methylsulfate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved FDF

                            Recipient : Avadel Pharmaceuticals

                            Deal Size : $42.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Avadel Sells Sterile Injectables Portfolio; will Focus on Narcolepsy

                            Details : Company announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz®, Vazculep®, and Akovaz®, as well as Nouress™ o Exela Sterile Medicines LLC.

                            Product Name : Bloxiverz

                            Product Type : Other Small Molecule

                            Upfront Cash : $14.5 million

                            January 07, 2020

                            Lead Product(s) : Neostigmine Methylsulfate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved FDF

                            Recipient : Avadel Pharmaceuticals

                            Deal Size : $42.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Exela Pharma Sciences, LLC.

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Exela Pharma Sciences, LLC.

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tranexamic Acid

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Tranexamic Acid in Spinal Fusion Surgery

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 08, 2018

                            Lead Product(s) : Tranexamic Acid

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Exela Pharma Sciences, LLC.

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Exela Pharma Sciences, LLC.

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ciprofloxacin

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            August 13, 2014

                            Lead Product(s) : Ciprofloxacin

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth